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For many years portal venous diversion has 
been used for the haemodynamic objectives of 
stopping or preventing haemorrhage from oeso-
phageal varices or. less commonly. to treat in-
tractable ascites. Since 1963. a new dimension 
has been added to the old operation of porta-
caval shunt by employing this procedure to 
alter favourably the course of three inborn er-
rors of metabolism: glycogen storage disease. 
hyperlipoproteinaemia and alpha-I-antitrypsin 
deficiency. In this chapter we will discuss the 
results and the potential postoperative risks of 
portal diversion for these new indications. as 
well as the possible mechanisms of benefit. 
MECHANISM OF PORTAL 
DIVERSION EFFECTS 
It has been increasingly appreciated during the 
last two decades that venous blood from the 
splanchnic viscera has liver-supporting qualities 
not found to the same degree in other kinds of 
arterial or venous blood.H . 36. 31. 31.39. 41 The 
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main splanchnic venous 'hepatotrophic' factors 
are almost certainly endogenous hormones of 
which the single most important is insulin. De-
privation of the liver of the so-called hepato-
trophic effects of portal blood has been noted 
under several experimental conditions (includ-
ing portacaval shunt) to cause hepatocyte atro-
phy. deglycogenation and fatty infiltration. 
With electron microscopic studies. relatively 
specific findings have been disruption and re-
duction of the rough endoplasmic reticulum 
(RER) and diminution of its lining polyribo-
somes. B . 32. J7. 38. J9. "I Since RER is the 'fac-
tory' of the cell. a consequent reduction in 
many biosynthetic processes would be expected. 
Numerous studies have verified this hypothesis. 
We will comment here upon examples chosen 
because of their clarity or because of their prob-
able or proven clinical significance. 
The effect of portal diversion upon hepatic 
lipid metabolism has been unusually well stu-
died. We demonstrated reductions of more than 
800 0 in canine hepatic cholesterol and triglycer-
ide synthesis. J 7 A similar dimin ution in choles-
terol and/or lipoprotein synthesis has been con-
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FlI.4I.1 The operation of 
portacavai"transposition that was 
used for the first two patients 
WIth glycogen storage disease who 
were treated with ponal diversion. 
Note that the central portal vein 
is revasculanzed wlIh vena caval 
blood. From Starzl et al. (1965).)) 
with kind pennission of the 
authors and the publisher. C. V. 
~osbyK 
.( 
"le.48.1 Infenor vena cavagram in ~arch 197) E9~ years postoptrathelyl in Colorado Patient 1. showing a patent C3nl-
portal anastomosis (arrow) under two conditions of dye injection. Significant flo\\ through the li'·er. as \\'ell as around it by 
the azygous and other collaterals. was well seen at ftuoroscopy. IVC=distal Inferior 'cna cava; LRV-kfl renal vein: 
PV '" portal vein. From Starzl et al. ( 19731."0 with kind pennission of the authors and the editor of Anlfllis of SIlTIer}', 
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firmed in/rats. dogs. swine and baboons: this 
has been reviewed elsewhere. J2 Reductions in 
hepatic lipid synthesis also have been docu-
mented in patients treated by us with portaca-
val shunt for familial hypercholesterolaemia 
(FH).'· o. 2l and it has been shown that total 
body cholesterol is gn~atly reduced.:l It may be 
considered proved that lipid homeostasis is al-
tered to an ex.traordinary degree by portacaval 
shunt. with the reduction in hepatic lipid 
synthesis being the greatest change. 
It has been equally well established that bile 
acid synthesis is greatly reduced by portacaval 
shunt. I. 2l. 32 Another synthetic pathway that 
has been well studied after portal diversion is 
the hepatic urea (Krebs-Henseleit) cycle. This 
has been shown by Reichle et al. to be de-. 
pressed by Eck fistula in rats 26 and dogs;O~ they 
also demonstrated a reduction in several of the 
enzymes involved in this metabolic pathway. 
As detailed studies are made of other hepatic 
synthetic or metabolic processes after portaca-
val shunt. it will not be surprising if all follow 
the same pattern. This possibility is supported 
by many studies during the past ) 5 years. sum-
marized elsewhere. J= which have shown that 
portacaval shunt lowers the activity of the 
hepatic microsomal mi:\ed-function enzyme sys-
tem. Aside from illustrating the principle of a 
wide-ranging decline in hepatic synthesis func-
tions after portacaval shunt. these observations 
are of potential specific importance because the 
microsomal. mix.ed-function enzyme system. for 
which multiple cytochrome P450 and P448 
species serve as terminal o:\idases. metabolizes 
a variety of drugs and foreign chemicals as well 
as endogenous compounds such as steroids and 
fatty acids. The depression of this broad-rang-
ing enzyme system would relate to many of the 
metabolic effects of portal diversion. 
GLYCOGENSTORAGE 
DISEASE (GSD) 
Portal diversion was first performed for glyco-
gen storage disease almost 20 years ago. Jl The 
rationale for the procedure was then naive by 
present day standards. It was hoped that by 
short-circuiting splanchnic venous blood 
around the liver. glucose would be made more 
readily available to peripheral tissues. with 
relief of the hypoglycaemia. and that the 
liver would be coincidentally deglycogenated. 
Subsequent animal experiments suggest that 
the consequences of portacaval shunt are far 
more subtle and wide-ranging than this simple 
view. 
That first patient. who had type 11\ glycogen 
storage disease. is still alive almostl 20 years 
after portacaval transposition. The bypassed 
portal venous blood was replaced \\ ith blood 
returning from the inferior \ena cava. an opera-
tion which was first described in animals by 
Child el af.3 (Figure 48.11. The transposition 
was used in order to avoid the potential hazards 
of Eck fistula. It was appreciated then. and 
amply confirmed since.2S· Jl that most animals. 
including subhuman primates. develop wasting 
and encephalopathy after portal diversion, but 
it was not appreciated that humans would be 
an exception to this generalization. 
Our first patient had a remarkably untroubled 
convalescence. An inferior vena cavagram almost 
ten years postoperatively revealed flow of sys-
temic venous blood from the distal vena cava 
to the liver but with a major bypass around 
the liver through azygous and hemiazygous 
collaterals (Figure 48.2). The degree of azygous 
bypassing was similar to that observed with a 
comparable angiographic study three months 
after the operation. 
Two more portacaval transpositIons were 
performed. one by Riddell el aUI In RiddeIrs 
patient. the cavoportal anastomosis clotted~l 
(Figure 48.3). The other attempt cost the life of 
our second patient~ the li,'er was unable to 
transmit the re·routed vena caval flow. causing 
hepatic swelling and uncontrollable acidosis. 
This seven-year-old child died two days later. 
\\'eH and Hermann and \fercer'" subsequently 
recommended that the simpler procedure of 
portacaval shunt be used. To our knowledge 
this approach has been followed in all later 
cases. By the spring of 1973"0 our own series of 
patients had reached se\en. and si:\ more had 
been formally reponed in the Iiterat ure from 
other centres. Since then our cases have in-
creased in number to ten (Table -*8.1). Type I 
disease (glucose-6-phosphatase deficiency) has 
been the most common indication for treat-
ment. with type III disease (amylo-l. 6-glucosi-
dase deficiency) being a distant second (Table 
48.1 ). 
Metabolic effects 
After portal diversion. most of the children who 
had preexisting hypoglycaemia did not obtain 
relief from this problem or the relief was not 
complete. Thus. night feedings usually had to 
be continued. Studies of plasma insulin and glu-
cagon in several of these patients have revealed 
-------- ._._-._-.. _._--------
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tal (b) 
Fie. 48.3 Studits of the Bnstol case of port<'caval transposition. The original operation was on 5 May 1965. and the 
eumination depicted was performed in December 1971 by Dr R.1. Sommerville at the Foothills Hospital. Calgary. Albena. 
<a) Inferior vena cavagram showing obstruction at the anastomotic site (arrow). IYC = distal inferior vena cava; LRY '" left 
renal vein. Note the extensive collaterals via the azygous system. (b) Demonstration of a patent ponacaval anastomosis 
(arrow) by means of a retrograde catheterization. IVC '" proximal inferior vena cava: PV '" ponal vein. From Stanl rl al. 
(1973).'0 with kmd permission of the authors and the editor of Annuls of SUT1(t'TY· 
changes (Figure 48.4). The flat peripheral insu-
lin curves typical of type I glycogen disease20 
became significantly elevated after portacaval 
shunt. and there were smaller increases in glu-
cagon. The glucose tolerance curves were very 
little different before and after operation. 
liver glycogen concentrations in all those 
patients who were later biopsied were not 
changed. In spite of this. in several of our 
patients and those reported by others the liver 
underwent a very obvious reductiOn in size as 
measured with liver scan planimetry. Even if 
obvious shrinkage did not occur. postoperative 
biopsies always showed a diminution in indivi-
dula hepatocyte size similar to that produced in 
animals by portacaval shunt.40 
In contrast to the incomplete relief of hypo-
glycaemia. there was profound and permanent 
relief of all components of the hyperlipidaemia 
whkh is a chara.:teristic of the type I disease 
(Figure 48.5). Correction of other metabolic de-
feelS was obsen~dK including abnormal bleed-
qabl~ 411.1 Patients With glycogen ~torage disease (GSD, tr.:atcd b~ portal diycr~hDn_ Patients I and ~ had portacaval 
[ranppyF~lflyDn: all,'th.:rs had portac;J\-al shunt. 
Pr.:opo.:rall\e s~mptom< 
PersIstent 
Patient Age GSD Hypogl)· GhlWth hypogl)caemla Survi\al 
number (years I type Date of operation caemia Acidosis retardation postopcrati\el) after shunt 
8 III IS October. 1963 Yts Yts Yes So Alive 19; years 
2 7 I 26 June. 1968 Yts Yts Yes Died 2 days 
3 7 I 2 May. 1972 Yts Yts Yts Yts· Alive II years 
~ II I 17 ~ayK 1972 Yes Yts Yts So Died 41 years 
5 10 \"1 :! August. 1972 Yes Ali~De 10; ~ears 
6 5 III 7 November. 1972 Yts Yts Yts So Alive 10! Y'ears 
7 3 III 8 November. 1972 Yts Yts Yts Yes" Ali,'e 10! years 
8 8 I 13 August. 1973 Yts Yts Yes vts~ Alive 9i years 
9 12 I 14 December. 1973 Yts Yts Yes Yts· Ali"" 9~ years 
10 I I 2 October. 1976 Yts Yts Yts Yts" Alive 6! years 
" <hemighl feeding via nasogastric tube starting O~ 4 years after ponaca"ai shunt. 
~ Undenooent orthotopic liver transplantation on I:! Februal10 1982. and is well 14 months latercsee Ie"''' 
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Fig.48.4 Plasma insulin and !!Iucose concentrations in response to an oral glucose tolerance test before and after portacnal 
shunt in a child (Patient 8. Table 48.1) with type I glycogen storage disease. 
ing. uric acid elevations and abnormal calcium 
metabolism. 40 These observations have been 
confirmed by others. 4 . 7. t9 
Gro,,·th 
All ten of our patients had growth retardation 
before portacaval shunt. Increases in height. 
which in most cases had virtually ceased, have 
occurred postoperatively at the rates listed in 
Table 48.:!. i.e. approximately O.5cm 'month. 
Quantitative measures of growth were 
obtained with radiographic techniques. 4o An 
example of the results is shown in Figure 48.6. 
Comparison of the wrist and hands in this 
seven-year-old stunted child before and II! 
months after operation showed the phenomenal 
effects of bone-age dOUbling. In addition to the 
size change. mineralization occurred. as did the 
appearance of new wrist bones. Circulating so-
matotrophin in these patients was normal. The 
growth spurts may have been at least partially 
attributable to the increased insulin distribution 
to the periphery mentioned earlier (see Figure 
48.4) since. in recent years. insulin has been 
recognized to be a major growth hormone. 
comparable in potency to somatotrophin. The 
simpler possibility that better nutrition was re-
sponsible must also be considered. 
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Time Idaysl 
FIt. 41.5 Effect of paRIIleral hyperali-
mentation and end-lo-side portacaval 
shunt on the plasma lipids of Patient 4. 
whose diagnosis was type 1 gl)cogen stor-
age disease. Note the rapid and relatively 
complete reversal of all abnormalities. 
From Starzl " al. (1973).·0 with kind per-
mission of the authon and the edilor of 
An"ols 0/ pllDf~rKD·K 
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TabW -'8.1 Gro"'th rate and coml'hcations after pun .. I diversi,'n f,'r gl>""l1o:n ~fIDrage disease. 
Growth rate lem month 
Patient number over oW I ~l months, Complications 
0,49 
~ Operau\o: death 
J O,SO Macroa.lenomatosis 
4 0.18 Died 4f years afl~r shunl. Primary pulmonary hypencnsl.'n: 
NH J = 8Sjlg. IOOml: m.l.:roadenomalosis 
5 0.S3 Renal anery slenosis surgically corrected 32 monlhs afler shunt 
6 06:! 
7 O,SO 
8 0.49 Macroadenomatosis, ll\'er transplantation after 8! years 
9 0.88 Renal stone IWO months after shunt. Mild anerial hypenension: ma-
croadcnomalosis 
10 0.4 Growth cessation after two years 
Mean 0.54 
Encephalopathy and other risks 
A patient who exhibited hepatic encepha-
lopathy eight years after end-to-side portacaval 
shunt for type I glycogen storage disease also 
developed multiple filling defects in her en-
larged liver. The diseased liver was replaced at 
transplantation. and all of the metabolic abnor-
malities of type I GSD were completely re-
lieved.%2 From the study of more than half-a-
dozen liver-based inborn errors of metabolism 
it has been shown that the phenotype of the 
transplanted organ permanently retains its ori-
ginal donor specificity.4Z 
One other child developed a blood ammonia 
concentration of 85 Jlgl 100 ml (normal < 60 Jig· 
100 ml for that laboratory). but there were no 
symptoms of encephalopathy. This patient died 
almost five years after portacaval shunt durin2 
an attempt at transcaval radiographic visuaJi: 
zation of the portacaval anastomosis. Except 
for the slightly elevated blood ammonia con-
centration, her standard liver functions were 
normal. At autopsy the liver had macroaden-
omatosis. very similar to that in the child who 
undern'ent liver transplantation. An autopsy 
finding that had not been suspected in life was 
advanced right ventricular hypertrophy and di-
latation. The smaller pulmonary arteries and 
arterioles had medial muscle hypertrophy. me-
dial and intimal fibrosis. scattered fibrinoid nec-
rosis. and numerous plexiform lesions. Such 
cardiopulmonary complications have been 
documented in other patients with type I GSD 
and other liver diseases. 18 This complication 
did not ha\e an obvious relationship to the por-
Fig. 48.6 The dramatic wriSI and hand bone growth and mineralization in Patient 3 with type I GSD in the first II ~ 
postoperative months. The bracket on the left index finger is Scm in length. From Slarzl rl al. (1973).40 with kind permissio~ 
of the authors and the edilor of Annul., o/SurRrr.,·, 
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Portacaval shunt 
t 
Days Months 
Fie. 41.7 Serum cholesterol concentrations after pona· 
caval shunt in Patient I of our FH series. 
tacaval shunt. The macroadenomatosis seen in 
these patients is very common in patients with 
type I GSO. and was recently reported in seven 
out of eight non-shunted patients aged 3 to 28 
years.l° 
The present status of portal diversion 
Portacaval shunt in the treatment of glycogen 
storage disease has been supplanted by the con-
tinuous night feeding schedule advocated by 
Greene el aJ. J 2 and Crigler and Folkman.5 Por-
tacaval shunt. if it has any role at all. is reserved 
for failures of this more conservative and 
liver-sparing approach. We have not performed 
a portacaval shunt since October 1916. 
FAMILIAL HYPER· 
CHOLESTEROLAEMIA (FH) 
I n March 1973. a I ~-year-old girl with homozy-
gous familial hypercholesterolaemia (FH) was 
treated with an end-to-side portacaval shunt; 
her serum cholesterol concentration fell 
markedlylS (Figure 48.71. In patients with this 
disease. there is an absence or deficienc,· of cell 
membrane lipoprotein receptors. IO . II ;nd thus 
a 'switch-off- mechanism to control lipid (espe-
cially cholesterol) synthesis is not present. 
By March 1982. we had treated 12 patients 
with FH in this wayK~g Eight of the patients 
were children. aged between 2 and 14 years. 
The four adults were aged 21. 31. 31 and 52 
years. All but two were homozygous for the FH 
abnonnality. low density lipoproteins (lOl) 
receptors were looked for by Goldstein and 
Brown lo . II on cultured fibroblasts obtained 
from aU patients and many of their close rela-
tives. Nine out of the ten patients with homo-
zygous disease were lOl-receptor negative and 
the other was receptor defective. Two of the 
patients had heterozygous disease. 
/ 
Effect upon serum lipids 
Total serum cholestrol concentratio~ fell sig-
nificantly in every patient I Figure 4'8.7) after 
portacaval shuntK~g The total cholesterol de-
clines rarilled from 20 to 55.4",. (average P~KUn .. ) 
and were ~maintained throughout the period of 
study. When measured. LDL cholesterols were 
reduced commensurately. HDL cholesterol 
and triglyceride levels were variably effected. 
Tendinocutaneous xanthomas regressed or 
disappeared in every patient (Figure 48.8) 
simultaneously with the fall in cholesterol 
concentration. 
Experience or otben in treating FH 
The consistency of the anticholesterolaemic re-
sponse was greater than that noted by other 
authors. who have reported a total of 26 addi-
tional patients.43 of whom 13 were treated in 
Johannesburg.8. ~ 5 
In the 13 patients treated elsewhere than Jo-
hannesburg (summarized in Starzl tt a/.43). 
serum cholesterol reductions of at least 30"" 
were obtained in ten at the same time as ten-
dinocutaneous xanthomas regressed. In two of 
the three exceptional patients. shunt thrombosis 
was proved and in one of thc:se the cholestc:rol 
fell by 40" 0 after a later mesocaval shunt. 6 In 
the third patient. reported by Soutar tt 01 .. 31 
there was prc:sumptive but not definitive evi-
dence of shunt occlusion. An early cholesterol 
fall of 40° 0 returned several months later to 
nearly preoperative values. At the same time. 
initially elevated serum glucagon Ic:\els. which 
are typically found with a patc:nt shunt. fc:1I to 
base line. 
:\lorbidity 
The invariable and long-lasting lipid lowering 
in our 12 patients was achieved without surgical 
morbidity. The physical development of those 
children who were nonnal before operation has 
proceeded. and the growth of those who were 
stunted before has moved towards nonnal. 
Emotional or intellectual deterioration second-
ary to the portal diversion has not occurred. 
although one child had an acute episode of 
encephalopathy which was managed with 
diet.4l 
,I 
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Fia·4II.8 The hands of Pallent I 
<,f the h~ pcrilpujaemla ""fl,-
IJlt"o "eeks bdtlrc; ... nu tj" It> 
monlhs after ponaciI\al .hun!. 
(b) 
Effect upon caniio\ascular disease 
(a) 
Patients with homozygous FH usually die of 
heart disease before the age of 20 years. The 
degree to which the cardiovascular complica-
tions of FH can be relieved or prevented by 
portal diversion has not been established. Re-
versal of aortic stenosis was seen in two of our 
patients. but regression of atheroma in the 
coronary arteries and aorta was not regularly 
accomplished.4l Small and ShipleylO have ex-
amined the factors which could preclude the 
reversal of atherosclerosis; some of these. 
including secondary fibrosis. would not be cor-
rected completely by the resorption of intra-
vascular xanthomas. Farriaux el 01.· have 
. 
\ 
suggested that anatomical stabilization of the 
vascular disease may be the best that can be 
hoped for with portacaval shunt. even in 
patients whose angina pectoris is relieved. Ex-
perience in se'·eral patients from our centre and 
elsewhere2 J. H. ,,- has shown the value of ag-
gressive surgical correction of technically re-
medial cardio .... ascular lesions in combination 
with portal diversion. Of greater importance 
will be the implementation of aggressive ther-
apy at a young age. before the development of 
irreversible cardiovascular complications. In 
patients with FH who are refractory to therapy 
with diet and medications. portacaval shunt 
may be- the treatment of choice. Post-
operatively. conservative treatment should be 
'"""'+111'4--"- ... ""I ... "IJIIUC .... "' .... , ... ,II!'I_ •• ________ __ K-KKK--~----
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tried again since further drops in post-shunt 
cholesterol levels h'l\e been seen using die~and 
medications which \\I!re previously ineffective. 
The staged combination of portacaval shunt 
and the ileal bypuss procedure of Buchwald t't 
ell. 2 has been tested in three patients. with an 
apparently additive effect~D ~ .. in spite of the fact 
that ileal bypass ak)ne has little or no effect in 
homozygous FH.2 In dogs. Guzman et ell.') 
have noted an additive effect of portal diversion 
by portacaval transposition plus ileal resection. 
Efforts by us .. 6 to document a complementary 
effect of ileal resection and portacaval shunt in 
dogs failed to confirm the claims of Guzman el 
al.. ll and a subsequent report by Rucker t't 
al. Z9 from the Minnesota study has shown that 
the additive effect originally reponed by Guz-
man el al. ! 3 was not sustained. 
Limitations of portacaul shunt 
Portacaval shunt. with or without supplemen-
tary treatment. provides only pallia tion for 
patients with FH. The amelioration of the ab-
normal metabolic patterns of FH has derived 
from the countervailing and potentially danger-
ous hepatic abnormalities caused by portacaval 
shunt." 3 The palliation is incomplete. since res-
toration of normal serum cholesterol values has 
not been achieved in any patient with homo-
zygous disease. It is possible that the metabolic 
abnormalities of FH could be rectified bv the 
ultimate step of liver transplantation. . 
AimeA-f-A~qfqovmpfk 
abcfCfb~Cv 
Patients with this disorder have a low le\el of 
plasma alpha-I-antitrypsin (an :x-globulin). and 
a high incidence of pulml)nary complications.·-
In 1969. a variable association of the: alpha-I-
antitrypsin deficiency with liver disease \\as rc-
ported. an obsena!ion that has had o\er-
whelming confirmation. 
The basis for the liver injury may be the 
hepatic production of an abnormal alpha-I-
antitrypsin which cannot be effectively trans-
ported out of the liver cells and which con-
sequently becomes sequestered within the 
hepatocytes near the rough endoplasmic reti-
culum. 1 S Irritation by the entrapped glyco-
protein has been the postulated cause of the 
hepatic cirrhosis. portal hypertension and 
hepatic failure that follow. The progressive and 
inexorable course that this pathogenesis implies 
may have discouraged attempts to treat 
complications of the portal hypertension (such 
as variceal haemorrhage) with portal-svstemic 
shunts. . 
We have performed end-to-side portacaval 
shunt in three children with the cirrhotic liver 
disease of alpha-I-antitrypsin deficiency."" The 
first two patients had had major haemorrhages 
from oesophageal varices. The third had ascites. 
but the principal reason for operation was the 
hope of influencing the metabolism of the 
alpha-I-antitrypsin. 
Follow-up at 3!. 5 and nearly 7 years were 
performedK"D~ Standard !i\er function tests have 
not changed greatly since the portacaval shunt. 
although the plasma ammonia levels have been 
elevated in both patients in whom this measure 
was systematically obtained. None of the three 
patients have had symptoms of encephalo-
pathy. although Patient:! had mental slowness 
for the first two postoperative years. 
All three patients had stabilization of a pre-
viously deteriorating clinical state. However. 
the most objective evidence that the natural his-
tory of the disease was favourably altered came 
from the histopathological studies of operative 
and postoperative biopsies in Patients 2 and 
3. 44 In Patient :!. a biopsy nine momhs after 
the portal diYersion showed that the number of 
hepatocytes that contained alpha-I-antitrypsin 
globules was diminished to :!8S o' compared 
with 38.::!" 0 at the time of the original opera-
tion. The hepatocytes were 220 0 smaller and the 
amount of rough endoplasmic reticulum in 
their cytoplasm was greatly reduced. 
In Patient 3. the percentage of hepatocytes 
containing alpha-I-antitrypsin. globules was 
44.5° 0 at tAe time of operation. and 48.:! and 
38.7"" at 7 and 13 months. respectively. after 
portacaval shunt. The hepatocytes were 15 and 
::!O" u smaller at these postoperative periods. The 
percentage of hepatocytes containing alpha-I-
antitrypsin ~lohule~ \\ as reduced to :!OA"" in 
the biopsy taken at :! years II months. The 
hepatocytes remained :0"" smaller than in the 
preoperative biopsy. and the amount of both 
rough and smooth endoplasmic reticulum in 
their cytoplasm was reduced. The severity of 
the macronodular cirrhosis was unaltered. 
Our assumption~" is that the portacaval shunt 
has diminished the synthesis of the abnor-
mal alpha~ I-antitrypsin. presumably by altering 
the function of the rough endoplasmic reticu-
lum and its ribosomes (see earlier) without 
commensurately reducing'the transport of this 
glycoprotein. With a better equilibrium between 
the production and transport of the :r-globulin. 
~~----KI--K -_¥.- -.-.. --~----------
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it is possible that its intracellular accumulation 
has been slo)'-'ed or probably even reversed. 
\ 
SLM\1ARY 
Complete portacaval shunt was used to treal 
ten patients with glycogen storage disease 
(GSO). A favourable effect was noted on body 
growth and a number of metabolic abnormali-
ties. More recently. continuous night feedings 
with an intermittently-placed gastric tube or 
through a gastrostomy have been shown to be 
helpful either before or after portacaval shunts. 
Such alimentation techniques have eliminated 
the need for shunts in almost all patients with 
GSO. 
Portacaval shunt was performed in ten 
patients with homozygous and two with heter-
ozygous familial hypercholesterolaemia (FH). 
Total serum cholesterol was lowered by be-
tween 20 and ppK4°~ during follow-up periods 
of 14 months to almost nine years. with com-
mensurate decreases in lOL cholesterol. The 
effect on HOl cholesterol and triglyceride \ev-
els was variable. Tendinocutaneous xanthomas 
diminished or disappeared. Growth and de-
velopment in children proceeded or accelerated. 
There was no detectable emotional or intellec-
tual deterioration. Hepatic failure did not 
occur. althou2h blood ammonia concentrations 
and serum alkaline phosphatase le\els increased 
relati\e to preoperative values. Cardiac symp-
toms were often improved. but evidence of re-
\ersal of cardio\ ascular lesions Yo as inconclu-
sive. Three patients with pre-existing heart 
disease died of cardiac complications after 4. 
18t and 30 months. Portacaval shunt has been 
eff~tive therapy for patients with FH Yo ho Yo ere 
refractory or intolerant to medical treatment: it 
should be performed before the de\elopment of 
irreversible cardiovascular damage. 
Three paediatric patients with the liver dis-
ease of alpha-I-antitrypsin deficiency and with 
complications of portal hypertension had end-
to-side portacaval shunts. Their clinical courses 
have been stabilized for between 3 t and almost 
se\'en years. Postoperative liver bi<ipsies of two 
of the patients showed the typical histopatho-
logical changes caused by portal diversion. as 
well as an apparent reduction in the quantity of 
alpha-I-antitrypsin particles in the hepatocytes. 
The metabolic changes caused by portal diver-
sion apparently have created a more favourable 
equilibrium between the synthesis and excretion 
of the abnormal alpha-I-antitrypsin. 
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